Notice of Annual General Meeting in Moberg Pharma AB (publ)

        Print
| Source: Moberg Derma AB
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”)
are hereby convened to the Annual General Meeting on Tuesday, May 13, 2014 at
5:00 p.m. in the Company´s premises in Bromma, address Gustavslundsvägen 42, 5
tr, 167 51 Bromma (Alviks torg), Sweden.
Attendance at the Annual General Meeting

Shareholders who wish to participate in the Annual General Meeting must:
-       Be recorded in the share register maintained by Euroclear Sweden AB
(“Euroclear”), on Wednesday, May 7, 2014, and
-   Give notice of attendance to the Company under address: Moberg Pharma AB
(publ), Gustavslundsvägen 42, 5 tr, 167 51 Bromma, att. Anna Ljung or by e-mail
to anna.ljung@mobergpharma.se, at the latest on Wednesday, May 7, 2014 at 4:00
p.m.

When giving notice of attendance, shareholders must state their name, civil
registration number or corporate registration number, address, telephone number
and, where applicable, number of accompanying assistants (no more than two).
Shareholders can participate and vote at the Meeting personally or by proxy.
Shareholders whose shares are registered in the name of a nominee must, in order
to be entitled to participate in the Annual General Meeting, with the help of
the nominee, re-register their shares in their own names in the share register
maintained by Euroclear, so that they are registered on Wednesday, May 7, 2014.

Shareholders represented by proxy should submit a power of attorney in original,
along with other authorization documents, when giving notice of attendance to
the Annual General Meeting. A power of attorney may be valid for up to five
years from issuance. The Company provides forms of power of attorney on the
Company´s website www.mobergpharma.se. Representatives of legal persons must
present a copy of the legal person’s certificate of registration or other
equivalent document demonstrating the right to act on behalf of the legal
person.

Number of shares and votes
As per the date of this notice, there are a total of 11,893,572 shares and votes
in the Company. The Company holds no own shares.

Proposed agenda

 1. Opening of the Meeting
 2. Election of Chairman of the Meeting
 3. Preparation and approval of the voting list
 4. Election of one or two persons to verify the minutes
 5. Determination whether the Meeting has been duly convened
 6. Approval of the agenda
 7. Presentation of the annual report and the audit report as well as the
consolidated accounts and the consolidated audit report
 8. Speech by the Chief Executive Officer, Peter Wolpert
 9. Resolutions on:
a) Adoption of the income statement and the balance sheet, as well as the
consolidated income statement and the consolidated balance sheet
b) Allocation of the Company’s result according to the adopted balance sheet
c) Discharge from liability of the Board members and the Chief Executive Officer
10. Determination of the number of Board members and deputy members
11. Determination of fees to the Board of Directors and Auditors
12. Election of the Board of Directors and Chairman of the Board of Directors
13. Proposal for resolution on principles for establishing the Nomination
Committee and its work
14. Proposal for resolution on principles for remuneration of senior executives
15. Proposal for resolution on Employee Stock Option Plan 2014
16. Proposal for resolution regarding authorization for the Board of Directors
to issue new shares
17. Closing of the Meeting

Proposals for resolution

Election of Chairman of the Meeting (Item 2)
The Nomination Committee of the Company, consisting of Per-Olof Edin, Chairman
of the Nomination Committee, representative of Östersjöstiftelsen, and the
members Henrik Blomquist, representative of Bure Equity AB (publ), Håkan Åström,
representative of SIX SIS AG, and Mats Pettersson, Chairman of the Board of
Directors, proposes that Mats Pettersson be elected as Chairman of the Annual
General Meeting.

Resolution on allocation of the Company’s result according to the adopted
balance sheet

(Item 9.b)

The Board of Directors proposes that no dividend should be paid for the fiscal
year 2013.

Election of the Board of Directors and Chairman of the Board of Directors and
determination of fees to the Board of Directors and Auditors (Items 10, 11 and
12)
The Nomination Committee proposes that the Board of Directors shall consist of
six (6) persons and no Deputies.

The Nomination Committee proposes re-election of Mats Pettersson, Wenche
Rolfsen, Torbjörn Koivisto, Geert Cauwenbergh and George Aitken-Davies for a
term of office extending until the end of the next Annual General Meeting, while
Peter Wolpert, Gustaf Lindewald and Peter Rothschild have declined re-election
and, thus, resign as board directors. In consultation with Peter Wolpert the
Nomination Committee has found it principally more correct to refine his
capacity at the Board Meetings, and that he will therefore only attend as CEO
and not as board director. Further, the Nomination Committee has proposed to
also appoint Thomas B. Thomsen as a Board Director. In addition, the Nomination
Committee proposes re-election of Mats Pettersson as Chairman of the Board of
Directors.

Thomas B. Thomsen has a broad international experience from senior positions
within the pharmacy industry with focus on OTC products, inter alia as Managing
Director of marketing companies within Pfizer and Johnson & Johnson, Senior Vice
President for OTC products within Reckitt Benckiser and Global Head of Category
at Novartis Consumer Health. Thomas B Thomsen is a Board Director of Cederroth
AB (Sweden) and Symprove PLC (England).

The Nomination Committee proposes an aggregate fee to Board members of SEK
1,000,000, of which SEK 300,000 to the Chairman, SEK 250,000 to the Deputy
Chairman and SEK 150,000 per member elected by the Annual General Meeting with
the exception of George Aitken-Davies.

It is noted that at the 2011 Annual General Meeting the auditing firm Ernst &
Young AB was appointed as the Company’s Auditor. It is noted that the authorized
public accountant Björn Ohlsson was appointed as Chief Auditor. The mandate runs
until the end of the 2015 Annual General Meeting.

The Nomination Committee proposes that fees to the Auditors, for a period until
the end of the 2015 Annual General Meeting, are to be paid as per approved
invoice.

Proposal for resolution on principles for establishing the Nomination Committee
and its work (Item 13)
The Nomination Committee proposes that the Annual General Meeting resolves on a
Nomination Committee in accordance with the following principles. The Annual
General Meeting assigns the Chairman of the Board of Directors to contact the
three largest shareholders in term of votes or owner groups (hereby referred to
both directly-registered shareholders and nominee-registered shareholders),
according to a transcript of the share register maintained by Euroclear Sweden
AB as per September 30, 2014, each appointing a representative to, besides the
Chairman of the Board of Directors, constitute the Nomination Committee for the
period until a new Nomination Committee is appointed by mandate from the next
Annual General Meeting.

If any of the three largest shareholders or owner groups declines to elect a
representative, the fourth largest shareholder or owner group will be asked, and
so on, until the Nomination Committee consists of four members. The majority of
the members of the Nomination Committee are to be independent of the Company and
its executive management. At least one member of the Nomination Committee is to
be independent of the Company´s largest shareholder in term of votes, or any
group of shareholders that act in concert in the governance of the Company.
Neither the Chief Executive Officer nor other members of the executive
management are to be members of the Nomination Committee. Board members may be
members of the Nomination Committee but may not constitute a majority thereof.
If more than one Board member is on the Nomination Committee, no more than one
of these may be dependent of a major shareholder in the Company. The Nomination
Committee appoints Chairman within the Committee. Neither the Chairman of the
Board of Directors nor any other Board member may be Chairman of the Nomination
Committee. The names of the members of the Nomination Committee shall be
announced no later than six months prior to the 2015 Annual General Meeting. In
the event that one of the members of the Nomination Committee resigns before the
Committee´s work is completed and if the Nomination Committee is of the opinion
that there is a need to replace the member, the Nomination Committee shall
appoint a new member according to the principles above, but based on a
transcript of the share register maintained by Euroclear Sweden AB, as soon as
possible after the member has resigned. A change in the composition of the
Nomination Committee shall be announced immediately. No fees shall be paid to
the members of the Nomination Committee for their work in the Nomination
Committee.

The Nomination Committee shall submit proposals on the following issues for
resolution by the 2015 Annual General Meeting:

a)    Proposal for Chairman of the Meeting
b)    Proposal for the Board of Directors
c)    Proposal for Chairman of the Board of Directors
d)    Proposal for fees to the Board of Directors, with distribution between the
Chairman and other Board members
e)    Proposal for Auditors
f)     Proposal for fee to Company Auditors
g)    Proposal for principles for establishing the Nomination Committee for the
2016 Annual General Meeting.

Proposal for resolution on principles for remuneration of senior executives
(Item 14)
The Board of Directors proposal for resolution on principles for remuneration of
senior executives is consistent with previous years´ principles for remuneration
and is mainly based on existing contracts between the Company and senior
executives.

The Board of Directors proposes that the Meeting resolves to adopt principles
for remuneration of senior executives on the following terms:

Moberg Pharma shall offer a total compensation at market rate that enables for
qualified senior executives to be recruited and retained. The compensation paid
to the Chief Executive Officer and other senior executives may consist of basic
salary, variable compensation, other benefits and pension benefits. The total
compensation is based on the basic salary and must be proportionate to the
executive’s responsibilities and authority. Variable compensation is capped at
25 - 50 per cent of each executive’s basic annual salary and is based on results
achieved in relation to individually defined qualitative and quantitative
targets as well as the Company´s result in relation to goals set by the Board of
Directors. Pensionable salary comprises only of basic salary. To the extent that
Board members perform work for the Company or any other Group Company, besides
work in the Board of Directors, consultancy fee at market rate may be paid.

The notice period shall be at least three months if the senior executive takes
the initiative and if the Company takes the initiative between three and twelve
months. Severance is not paid. The Meeting shall, when applicable, decide on all
share and share-price related programs. Allotment shall be made in accordance
with the resolution of the Shareholders’ Meeting. With the exception of the
employee stock options allotted and accrued, and what is provided for under
existing employment contracts as referred to above, senior executives are not
entitled to any benefits after the termination of the employment/assignment. The
Board of Directors shall be entitled to deviate from the above mentioned
principles for remuneration of senior executives if there are special reasons.

Proposal for resolution on Employee Stock Option Plan (Item 15)
The Board of Directors proposes that the Annual General Meeting (i) resolve to
adopt an employee stock option plan for 2014 for employees in the Company and in
the Company’s wholly-owned subsidiary Moberg Pharma North America LLC (”Moberg
North America”), (ii) resolve on issue of warrants to the Company’s wholly-owned
subsidiary Moberg Derma Incentives AB, reg. no. 556750-1589, (”Incentives”) for
the fulfillment of the Company’s commitments under the employee stock option
plan, and (iii) approve transfer of warrants or shares in the Company to
employees in the Company and Moberg North America.

(i) Employee Stock Option Plan 2014
The Board of Directors proposes that the Annual General Meeting resolves to
adopt Employee Stock Option Plan 2014 on principally the following terms:

The Board of Directors and the Chief Executive Officer are entitled to, within
the scope of the employee stock option plan, resolve on allotment of maximum
213, 500 employee stock options to key personnel in the Company and Moberg North
America. It will be permissible to allot a maximum of 50,000 employee stock
options per plan participant. The Board of Directors and the Chief Executive
Officer shall decide which persons shall be encompassed by the Employee Stock
Option Plan based on position, qualification and individual performance. The
maximum allotment may be adjusted proportionally based on each person's time as
an employee in the Company. The employee stock option plan will include the
following senior executives in the Company; Anna Ljung, Kjell Rensfeldt, Martin
Ingman, Peter Wolpert and Steve Cagle. The three first mentioned are proposed to
be allotted 15,000 employee stock options each and the two last mentioned are
proposed to be allotted 50,000 employee stock options each. Participants in the
employee stock option plan shall be allotted the employee stock options free of
charge. The allotment of employee stock options will take place immediately, in
connection with the 2014 Annual General Meeting.

Each employee stock option shall entitle the holder to subscribe for one (1) new
share in the Company at a subscription price equivalent to 110 per cent of the
volume-weighted average price paid for a share in the Company on the NASDAQ OMX
Stockholm during ten trading days following the 2014 Annual General Meeting,
however never less than the share quotient value. The employee stock options can
be used for subscription of new shares from June 30, 2017 until December 31,
2018. The employee stock options are linked to employment in the Company. The
employee stock options will be cancelled if the employment in the Company is
terminated and the employee at that time had not earned them. The employee stock
options earned by the employee before the time of termination shall be used for
subscription no later than six months thereafter. The employee stock options are
non-transferable.

In view of the above proposed terms, the size of the allotment and other
circumstances, the Board of Directors assesses that the proposed employee stock
option plan is well-balanced and that it will be beneficial for the Company and
its shareholders.

(ii) Issue of warrants to Incentives
In order to secure the Company’s commitments under Employee Stock Option Plan
2014 the Board of Directors proposes that the Annual General Meeting resolves on
an issue of a maximum of 258,692 warrants, whereof a maximum of 45,192 warrants
are intended to hedge the costs (mainly social security contributions or
corresponding taxes) that may arise from the employee stock option plan, on
principally the following terms:

The warrants shall be issued free of charge and the right to subscription shall,
with a deviation from the preferential right of the shareholders, be assigned to
Incentives. Subscription of warrants shall take place at the latest on May 20,
2014, with the right for the Board of Directors to extend the subscription
period. Each warrant shall entitle the holder to subscribe for one (1) new share
in the Company at a subscription price equivalent to 110 per cent of the volume
-weighted average price paid for a share in the Company on the NASDAQ OMX
Stockholm during ten trading days following the 2014 Annual General Meeting,
however never less than the share quotient value. Subscription for new shares in
the Company with the support of the warrants shall take place no later than
December 31, 2018. The new shares will entitle to dividend for the first time on
the record date that occurs after the new shares has been registered at the
Swedish Companies Registration Office (Sw: Bolagsverket) and after the shares
have been recorded in the share register maintained by Euroclear Sweden AB.

In the event that all warrants issued in respect of Employee Stock Option Plan
2014 are used to subscribe for new shares, the Company’s share capital will
increase by SEK 25,869.20 from SEK 1,189,357.20 to SEK 1,215,226.40. This is
equivalent to a dilution of approximately 2 per cent of the shares and votes in
the Company.

The reasons for deviating from the shareholders’ preferential rights are that
the issue constitutes part of the implementation of Employee Stock Option Plan
2014. The Board of Directors assesses that a long-term personal ownership
commitment among the employees will lead to an increased interest in the
business and the result, and therefore improves the motivation of the employees.
It is advantageous for the Company to be able to offer employees an opportunity
to participate in the Company's development. The Board of Directors therefore
assesses that the proposal, with regard to the terms, appears to be reasonable.

(iii) Approval of transfer of warrants or shares in the Company to employees in
the Company, etc.
The Board of Directors proposes that the Annual General Meeting resolves to
approve that Incentives is entitled to transfer warrants or shares in the
Company to personnel in the Company and Moberg North America, who have received
employee stock options under the Employee Stock Option Plan 2014, or otherwise
dispose of the warrants, in order to secure the Company’s commitments and costs
in connection with Employee Stock Option Plan 2014.

Costs for Employee Stock Option Plan 2014
The Board of Directors assesses that Employee Stock Option Plan 2014 will lead
to costs partly in the form of accounting salary costs, partly in the form of
social security contributions. These latter costs are hedged by the warrants
issued with the purpose of covering these costs.

Preparation of the proposal of Employee Stock Option Plan 2014
The proposal regarding Employee Stock Option Plan 2014 has been prepared by the
Company's Remuneration Committee and has been presented to the Board of
Directors.

Previous incentive programs in the Company
For a description of the Company’s other share-related incentive programs,
reference is made to the Company’s 2013 annual report, and the Company’s website
www.mobergpharma.com. In addition to the programs described, there are no other
share-related incentive programs in the Company.

Majority requirement
The Annual General Meeting´s resolution on the above items (i) – (iii) shall be
adopted together as one resolution. A resolution in accordance with the Board of
Director’s proposal requires the approval of shareholders representing at least
nine tenths of the votes cast and the shares represented at the Meeting.

Proposal for resolution regarding authorization for the Board of Directors to
issue new shares (Item 16)
The Board of Directors proposes that the Annual General Meeting authorize the
Board of Directors to, within the scope of the articles of association, with or
without deviation from the shareholders’ preferential right, on one or several
occasions during the period until the next Annual General Meeting, resolve to
increase the Company’s share capital by issuing new shares in the Company. The
total number of shares issued in accordance with this authorization may be
equivalent to a maximum of 20 per cent of the shares in the Company at the time
of the 2014 Annual General Meeting. The issues shall be made with issue rates at
market rate, and where applicable be subject to issue discount at market rate,
and payment shall, apart from payment in cash, be made in kind or by set-off or
otherwise with conditions. The purpose of the authorization and the reasons for
any deviation from the shareholders’ preferential right is that the Company
shall be able to carry out issues in order to finance the Company’s business,
commercialization and development of the Company’s products and/or the
acquisition of products, project portfolios, businesses, companies or parts of
companies.

The Board of Directors, CEO or such person as the Board of Directors authorize,
shall be authorized to carry out amendments and clarifications of the Annual
General Meeting’s decisions that are required in connection with the filing with
the Companies Registration Office.

A resolution in accordance with this proposal requires the approval of
shareholders representing at least two thirds of the votes cast and the shares
represented at the Meeting.

Information at the Annual General Meeting
Shareholders may request that the Board of Directors and the Chief Executive
Officer provide information regarding circumstances that may affect the
assessment of an item on the agenda for the Annual General Meeting, and
circumstances that can affect the assessment of the Company’s financial
position. The Board of Directors and the Chief Executive Officer shall provide
such information at the Annual General Meeting if they believe that it can be
done without material harm to the Company. Shareholders wishing to submit
questions in advance may send them to Moberg Pharma AB (publ), att. Anna Ljung,
Gustavslundsvägen 42, 5 tr, 167 51 Bromma, Sweden, or by e-mail to
anna.ljung@mobergpharma.se.

Documents
Copies of accounting documents and the audit report as well as forms of power of
attorney will be available for shareholders at the Company and on the Company´s
website www.moberpharma.com, as from Wednesday, April 16, 2014. Complete
proposals as well as other documents according to the Swedish Companies Act will
be available for shareholders at the Company and on the Company´s website as
above, no later than Tuesday, April 22, 2014. All of these documents will also,
without charge, be sent to shareholders who so request and state their address.

_______________________________________

Stockholm in April 2014

Moberg Pharma AB (publ)

The Board of Directors

About this information
Moberg Pharma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 8:30 am (CET) on April 14th, 2014.